肠道纤维化与肝纤维化：慢性炎症的后果还是独立的病理生理学过程？
Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?
作者信息
Rieder Florian, Bettenworth Dominik, Imai Jin, Inagaki Yutaka
机构信息
Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland, Ohio, USA.
Department of Pathobiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
出版信息
Inflamm Intest Dis. 2016 Apr;1(1):41-49. doi: 10.1159/000445135. Epub 2016 Mar 19.
Abstract
BACKGROUND
Intestinal fibrosis and liver fibrosis represent a significant burden for our patients and health-care systems. Despite the severe clinical problem and the observation that fibrosis is reversible, no specific antifibrotic therapies exist.
SUMMARY
In this review, using an 'East-West' scientific collaboration, we summarize the current knowledge on principal mechanisms shared by intestinal fibrosis and liver fibrosis. We furthermore discuss inflammation as the cause of fibrogenesis in both entities, depict unique features of intestinal and hepatic fibrosis, and provide a future outlook on the development of antifibrotic therapies.
KEY MESSAGES
A collaborative effort in the field of fibrosis, covering multiple organ systems, will have the highest chance of leading to the development of a successful antifibrotic intervention.
摘要
背景
肠道纤维化和肝纤维化给患者及医疗系统带来了沉重负担。尽管纤维化是一个严重的临床问题，且有研究表明其具有可逆性，但目前尚无特异性抗纤维化疗法。
总结
在本综述中，我们通过“东西方”科学合作，总结了目前关于肠道纤维化和肝纤维化共同主要机制的知识。我们还讨论了炎症作为这两种疾病纤维化形成原因的相关内容，描述了肠道和肝纤维化的独特特征，并对抗纤维化疗法的未来发展前景进行了展望。
关键信息
纤维化领域跨多个器官系统的合作努力，最有可能促成成功的抗纤维化干预措施的研发。
相似文献
1
Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?肠道纤维化与肝纤维化：慢性炎症的后果还是独立的病理生理学过程？
Inflamm Intest Dis. 2016 Apr;1(1):41-49. doi: 10.1159/000445135. Epub 2016 Mar 19.
2
Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies.肝纤维化的逆转：抗纤维化治疗的病理生理基础
Hepat Med. 2011 Jul 4;3:69-80. doi: 10.2147/HMER.S9051.
3
Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices.利用小鼠精准切割组织切片探索纤维发生的器官特异性特征。
Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;1866(1):165582. doi: 10.1016/j.bbadis.2019.165582. Epub 2019 Oct 30.
4
Liver fibrosis: Direct antifibrotic agents and targeted therapies.肝纤维化：直接抗纤维化药物和靶向治疗。
Matrix Biol. 2018 Aug;68-69:435-451. doi: 10.1016/j.matbio.2018.04.006. Epub 2018 Apr 12.
5
CREB family: A significant role in liver fibrosis.CREB 家族：在肝纤维化中具有重要作用。
Biochimie. 2019 Aug;163:94-100. doi: 10.1016/j.biochi.2019.05.014. Epub 2019 May 18.
6
Antifibrotic therapy in chronic liver disease.慢性肝病的抗纤维化治疗
Clin Gastroenterol Hepatol. 2005 Feb;3(2):95-107. doi: 10.1016/s1542-3565(04)00445-8.
7
Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.将对肝纤维化发病机制的理解转化为新的治疗方法。
Clin Gastroenterol Hepatol. 2013 Mar;11(3):224-31.e1-5. doi: 10.1016/j.cgh.2013.01.005. Epub 2013 Jan 7.
8
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis.细胞组织纤维化的机制。5. 肝脏纤维化的新见解。
Am J Physiol Cell Physiol. 2013 Oct 15;305(8):C789-99. doi: 10.1152/ajpcell.00230.2013. Epub 2013 Jul 31.
9
Efficacy and safety of anti-hepatic fibrosis drugs.抗肝纤维化药物的疗效与安全性。
World J Gastroenterol. 2020 Nov 7;26(41):6304-6321. doi: 10.3748/wjg.v26.i41.6304.
10
An update on the recent advances in antifibrotic therapy.抗纤维化治疗的最新进展综述。
Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1143-1152. doi: 10.1080/17474124.2018.1530110. Epub 2018 Oct 3.
引用本文的文献
1
TWISTed fibroblasts: New drivers of intestinal fibrosis in Crohn's disease.TWIST 阳性成纤维细胞：克罗恩病肠道纤维化的新驱动因素
Heliyon. 2024 Nov 24;10(23):e40604. doi: 10.1016/j.heliyon.2024.e40604. eCollection 2024 Dec 15.
2
The Role of Genetic and Epigenetic Regulation in Intestinal Fibrosis in Inflammatory Bowel Disease: A Descending Process or a Programmed Consequence?遗传和表观遗传调控在炎症性肠病肠道纤维化中的作用：是一个下行过程还是程序性后果？
Genes (Basel). 2023 May 27;14(6):1167. doi: 10.3390/genes14061167.
3
What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature.非酒精性脂肪性肝病、肝纤维化和炎症性肠病有何共同之处？当前文献综述。
Metabolites. 2023 Mar 3;13(3):378. doi: 10.3390/metabo13030378.
4
Therapeutic Potential of the Combination of Pentoxifylline and Vitamin-E in Inflammatory Bowel Disease: Inhibition of Intestinal Fibrosis.己酮可可碱与维生素E联合应用于炎症性肠病的治疗潜力：抑制肠道纤维化
J Clin Med. 2022 Aug 12;11(16):4713. doi: 10.3390/jcm11164713.
5
Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease Fibrosis.上皮内质网应激和前梯度蛋白 2 同源物在克罗恩病纤维化中的潜在作用。
J Crohns Colitis. 2021 Oct 7;15(10):1737-1750. doi: 10.1093/ecco-jcc/jjab061.
6
Mechanism of fibrosis and stricture formation in Crohn's disease.克罗恩病纤维化和狭窄形成的机制。
Scand J Immunol. 2020 Dec;92(6):e12990. doi: 10.1111/sji.12990.
7
Pathology of Fibrosis in Crohn's Disease-Contribution to Understanding Its Pathogenesis.克罗恩病纤维化的病理学——对理解其发病机制的贡献
Front Med (Lausanne). 2020 May 5;7:167. doi: 10.3389/fmed.2020.00167. eCollection 2020.
8
Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice.抑制纤溶酶原激活物抑制剂-1可减轻小鼠肠道纤维化。
Intest Res. 2020 Apr;18(2):219-228. doi: 10.5217/ir.2019.00037. Epub 2020 Feb 17.
9
Umbilical cord/placenta-derived mesenchymal stem cells inhibit fibrogenic activation in human intestinal myofibroblasts via inhibition of myocardin-related transcription factor A.脐带/胎盘源性间充质干细胞通过抑制心肌营养素相关转录因子 A 抑制人肠道肌成纤维细胞的纤维生成激活。
Stem Cell Res Ther. 2019 Sep 23;10(1):291. doi: 10.1186/s13287-019-1385-8.
10
Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases.肠类器官/器官样体：炎症性肠病药物发现的新平台。
World J Gastroenterol. 2019 Aug 14;25(30):4125-4147. doi: 10.3748/wjg.v25.i30.4125.
本文引用的文献
1
Anti-fibrotic effects of a novel small compound on the regulation of cytokine production in a mouse model of colorectal fibrosis.一种新型小分子化合物对结直肠纤维化小鼠模型中细胞因子产生调节的抗纤维化作用
Biochem Biophys Res Commun. 2015 Dec 25;468(4):554-60. doi: 10.1016/j.bbrc.2015.10.123. Epub 2015 Nov 19.
2
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.成人慢性乙型肝炎病毒感染的抗病毒治疗：系统评价和荟萃分析。
Hepatology. 2016 Jan;63(1):284-306. doi: 10.1002/hep.28280. Epub 2015 Nov 13.
3
Gastrointestinal Fibroblasts Have Specialized, Diverse Transcriptional Phenotypes: A Comprehensive Gene Expression Analysis of Human Fibroblasts.胃肠道成纤维细胞具有特异、多样的转录表型：人类成纤维细胞的全面基因表达分析
PLoS One. 2015 Jun 5;10(6):e0129241. doi: 10.1371/journal.pone.0129241. eCollection 2015.
4
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.蒙歌根，一种口服 SMAD7 反义寡核苷酸，与克罗恩病。
N Engl J Med. 2015 Mar 19;372(12):1104-13. doi: 10.1056/NEJMoa1407250.
5
Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease.非经典 STAT3 激活调节狭窄型克罗恩病肌肉中过量的转化生长因子-β1 和 I 型胶原蛋白表达。
J Immunol. 2015 Apr 1;194(7):3422-31. doi: 10.4049/jimmunol.1401779. Epub 2015 Mar 4.
6
Hepatitis C.丙型肝炎
Lancet. 2015 Mar 21;385(9973):1124-35. doi: 10.1016/S0140-6736(14)62401-6. Epub 2015 Feb 14.
7
Pathobiology of liver fibrosis: a translational success story.肝纤维化的病理生物学：一个转化医学的成功案例。
Gut. 2015 May;64(5):830-41. doi: 10.1136/gutjnl-2014-306842. Epub 2015 Feb 13.
8
Inhibition of the interleukin-23/interleukin-17 pathway by anti-interleukin-23p19 monoclonal antibody attenuates 2,4,6-trinitrobenzene sulfonic acid-induced Crohn's disease in rats.抗白细胞介素-23p19单克隆抗体对白细胞介素-23/白细胞介素-17通路的抑制作用可减轻2,4,6-三硝基苯磺酸诱导的大鼠克罗恩病。
Mol Med Rep. 2014 Oct;10(4):2105-10. doi: 10.3892/mmr.2014.2427. Epub 2014 Jul 28.
9
Hepatitis B virus infection.乙型肝炎病毒感染。
Lancet. 2014 Dec 6;384(9959):2053-63. doi: 10.1016/S0140-6736(14)60220-8. Epub 2014 Jun 18.
10
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.来迪派韦索磷布韦片治疗既往治疗的 HCV 基因 1 型感染。
N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.
Zotero 插件